These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 36992294)

  • 41. Effects of a booster dose of BNT162b2 on spike-binding antibodies to SARS-CoV-2 Omicron BA.2, BA.3, BA.4 and BA.5 subvariants in infection-naïve and previously-infected individuals.
    Kuzel TG; Fu J; Anderson M; Stec M; Boler M; Behun D; Gosha A; Cloherty G; Landay A; Moy J
    Vaccine; 2023 Jan; 41(4):879-882. PubMed ID: 36572601
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Probing Mechanisms of Binding and Allostery in the SARS-CoV-2 Spike Omicron Variant Complexes with the Host Receptor: Revealing Functional Roles of the Binding Hotspots in Mediating Epistatic Effects and Communication with Allosteric Pockets.
    Verkhivker G; Agajanian S; Kassab R; Krishnan K
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232845
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antibodies that neutralize all current SARS-CoV-2 variants of concern by conformational locking.
    Liu L; Casner RG; Guo Y; Wang Q; Iketani S; Chan JF; Yu J; Dadonaite B; Nair MS; Mohri H; Reddem ER; Yuan S; Poon VK; Chan CC; Yuen KY; Sheng Z; Huang Y; Bloom JD; Shapiro L; Ho DD
    bioRxiv; 2023 Apr; ():. PubMed ID: 37090592
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Computationally restoring the potency of a clinical antibody against SARS-CoV-2 Omicron subvariants.
    Desautels TA; Arrildt KT; Zemla AT; Lau EY; Zhu F; Ricci D; Cronin S; Zost SJ; Binshtein E; Scheaffer SM; Dadonaite B; Petersen BK; Engdahl TB; Chen E; Handal LS; Hall L; Goforth JW; Vashchenko D; Nguyen S; Weilhammer DR; Lo JK; Rubinfeld B; Saada EA; Weisenberger T; Lee TH; Whitener B; Case JB; Ladd A; Silva MS; Haluska RM; Grzesiak EA; Earnhart CG; Hopkins S; Bates TW; Thackray LB; Segelke BW; Lillo AM; Sundaram S; Bloom J; Diamond MS; Crowe JE; Carnahan RH; Faissol DM
    bioRxiv; 2023 Apr; ():. PubMed ID: 36324800
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An engineered ACE2 decoy neutralizes the SARS-CoV-2 Omicron variant and confers protection against infection in vivo.
    Ikemura N; Taminishi S; Inaba T; Arimori T; Motooka D; Katoh K; Kirita Y; Higuchi Y; Li S; Suzuki T; Itoh Y; Ozaki Y; Nakamura S; Matoba S; Standley DM; Okamoto T; Takagi J; Hoshino A
    Sci Transl Med; 2022 Jun; 14(650):eabn7737. PubMed ID: 35471044
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term variations and potency of neutralizing antibodies against Omicron subvariants after CoronaVac-inactivated booster: A 7-month follow-up study.
    Li X; Yin Y; Cui Q; Huang W; Zou Q; Shen T
    J Med Virol; 2023 Jan; 95(1):e28279. PubMed ID: 36329634
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antibody escape and cryptic cross-domain stabilization in the SARS-CoV-2 Omicron spike protein.
    Javanmardi K; Segall-Shapiro TH; Chou CW; Boutz DR; Olsen RJ; Xie X; Xia H; Shi PY; Johnson CD; Annapareddy A; Weaver S; Musser JM; Ellington AD; Finkelstein IJ; Gollihar JD
    Cell Host Microbe; 2022 Sep; 30(9):1242-1254.e6. PubMed ID: 35988543
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Full-spike deep mutational scanning helps predict the evolutionary success of SARS-CoV-2 clades.
    Dadonaite B; Brown J; McMahon TE; Farrell AG; Asarnow D; Stewart C; Logue J; Murrell B; Chu HY; Veesler D; Bloom JD
    bioRxiv; 2023 Nov; ():. PubMed ID: 38014024
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Biparatopic antibody BA7208/7125 effectively neutralizes SARS-CoV-2 variants including Omicron BA.1-BA.5.
    Wang Y; Yan A; Song D; Dong C; Rao M; Gao Y; Qi R; Ma X; Wang Q; Xu H; Liu H; Han J; Duan M; Liu S; Yu X; Zong M; Feng J; Jiao J; Zhang H; Li M; Yu B; Wang Y; Meng F; Ni X; Li Y; Shen Z; Sun B; Shao X; Zhao H; Zhao Y; Li R; Zhang Y; Du G; Lu J; You C; Jiang H; Zhang L; Wang L; Dou C; Liu Z; Zhao J
    Cell Discov; 2023 Jan; 9(1):3. PubMed ID: 36609558
    [TBL] [Abstract][Full Text] [Related]  

  • 50. SARS-CoV-2 omicron spike simulations: broad antibody escape, weakened ACE2 binding, and modest furin cleavage.
    Jawaid MZ; Baidya A; Mahboubi-Ardakani R; Davis RL; Cox DL
    Microbiol Spectr; 2023 Aug; 11(5):e0121322. PubMed ID: 37650619
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission.
    Shrestha LB; Foster C; Rawlinson W; Tedla N; Bull RA
    Rev Med Virol; 2022 Sep; 32(5):e2381. PubMed ID: 35856385
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Characterization of Omicron BA.4.6, XBB, and BQ.1.1 subvariants in hamsters.
    Halfmann PJ; Iwatsuki-Horimoto K; Kuroda M; Hirata Y; Yamayoshi S; Iida S; Uraki R; Ito M; Ueki H; Furusawa Y; Sakai-Tagawa Y; Kiso M; Armbrust T; Spyra S; Maeda K; Wang Z; Imai M; Suzuki T; Kawaoka Y
    Commun Biol; 2024 Mar; 7(1):331. PubMed ID: 38491227
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An engineered ACE2 decoy receptor can be administered by inhalation and potently targets the BA.1 and BA.2 omicron variants of SARS-CoV-2.
    Zhang L; Narayanan KK; Cooper L; Chan KK; Devlin CA; Aguhob A; Shirley K; Rong L; Rehman J; Malik AB; Procko E
    bioRxiv; 2022 Mar; ():. PubMed ID: 35378764
    [TBL] [Abstract][Full Text] [Related]  

  • 54. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants.
    Westendorf K; Žentelis S; Wang L; Foster D; Vaillancourt P; Wiggin M; Lovett E; van der Lee R; Hendle J; Pustilnik A; Sauder JM; Kraft L; Hwang Y; Siegel RW; Chen J; Heinz BA; Higgs RE; Kallewaard NL; Jepson K; Goya R; Smith MA; Collins DW; Pellacani D; Xiang P; de Puyraimond V; Ricicova M; Devorkin L; Pritchard C; O'Neill A; Dalal K; Panwar P; Dhupar H; Garces FA; Cohen CA; Dye JM; Huie KE; Badger CV; Kobasa D; Audet J; Freitas JJ; Hassanali S; Hughes I; Munoz L; Palma HC; Ramamurthy B; Cross RW; Geisbert TW; Menacherry V; Lokugamage K; Borisevich V; Lanz I; Anderson L; Sipahimalani P; Corbett KS; Yang ES; Zhang Y; Shi W; Zhou T; Choe M; Misasi J; Kwong PD; Sullivan NJ; Graham BS; Fernandez TL; Hansen CL; Falconer E; Mascola JR; Jones BE; Barnhart BC
    bioRxiv; 2022 Mar; ():. PubMed ID: 33972947
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In Vitro Efficacy of Antivirals and Monoclonal Antibodies against SARS-CoV-2 Omicron Lineages XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1.
    Pochtovyi AA; Kustova DD; Siniavin AE; Dolzhikova IV; Shidlovskaya EV; Shpakova OG; Vasilchenko LA; Glavatskaya AA; Kuznetsova NA; Iliukhina AA; Shelkov AY; Grinkevich OM; Komarov AG; Logunov DY; Gushchin VA; Gintsburg AL
    Vaccines (Basel); 2023 Sep; 11(10):. PubMed ID: 37896937
    [TBL] [Abstract][Full Text] [Related]  

  • 56. SARS-CoV-2 variants of concern: spike protein mutational analysis and epitope for broad neutralization.
    Mannar D; Saville JW; Sun Z; Zhu X; Marti MM; Srivastava SS; Berezuk AM; Zhou S; Tuttle KS; Sobolewski MD; Kim A; Treat BR; Da Silva Castanha PM; Jacobs JL; Barratt-Boyes SM; Mellors JW; Dimitrov DS; Li W; Subramaniam S
    Nat Commun; 2022 Aug; 13(1):4696. PubMed ID: 35982054
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.
    Belik M; Liedes O; Vara S; Haveri A; Pöysti S; Kolehmainen P; Maljanen S; Huttunen M; Reinholm A; Lundberg R; Skön M; Österlund P; Melin M; Hänninen A; Hurme A; Ivaska L; Tähtinen PA; Lempainen J; Kakkola L; Jalkanen P; Julkunen I
    Front Immunol; 2023; 14():1099246. PubMed ID: 36756112
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A multispecific antibody prevents immune escape and confers pan-SARS-CoV-2 neutralization.
    Misasi J; Wei RR; Wang L; Pegu A; Wei CJ; Oloniniyi OK; Zhou T; Moliva JI; Zhao B; Choe M; Yang ES; Zhang Y; Boruszczak M; Chen M; Leung K; Li J; Yang ZY; Andersen H; Carlton K; Godbole S; Harris DR; Henry AR; Ivleva VB; Lei P; Liu C; Longobardi L; Merriam JS; Nase D; Olia AS; Pessaint L; Porto M; Shi W; Wolff JJ; Douek DC; Suthar MS; Gall J; Koup RA; Kwong PD; Mascola JR; Nabel GJ; Sullivan NJ
    bioRxiv; 2022 Nov; ():. PubMed ID: 35982683
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses.
    Li M; Ren Y; Aw ZQ; Chen B; Yang Z; Lei Y; Cheng L; Liang Q; Hong J; Yang Y; Chen J; Wong YH; Wei J; Shan S; Zhang S; Ge J; Wang R; Dong JZ; Chen Y; Shi X; Zhang Q; Zhang Z; Chu JJH; Wang X; Zhang L
    Nat Commun; 2022 Dec; 13(1):7957. PubMed ID: 36575191
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An ACE2-Based Decoy Inhibitor Effectively Neutralizes SARS-CoV-2 Omicron BA.5 Variant.
    Zhang H; Hu B; Lv P; Liu Y; Guo M; Wu Z; Zhou K; Dai M; Yu X; Liu Z; Yu B; Xu L; Guo M; Cai K; Li Y
    Viruses; 2022 Oct; 14(11):. PubMed ID: 36366484
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.